Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Aspire Health vs FuturHealth

Aspire Health
Graded #346

Lower grade

vs+6.3999999999999915
FuturHealth
Graded #215

Higher grade

The verdict

FuturHealth takes it — 65.6/100 to 59.2/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +15
45
60
Dose & formulationFuturHealth +28
53
81
Clinical oversightAspire Health +17
84
67
Labs & monitoringAspire Health +5
66
61
FulfillmentFuturHealth +1
61
62
Contract termsFuturHealth +14
41
55
Aspire Health · left barFuturHealth · right bar

The numbers

MetricAspire HealthFuturHealth
WeighScore59.2/10065.6/100
GradeCC
Scorecard rank#346#215
SemaglutideNot disclosed$199/mo (compounded)
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Aspire Health

Graded #346 · C

Strengths

  • Both compounded and brand-name options (Wegovy + Zepbound) — rare among GLP-1 telehealth providers
  • Lab orders with interpretation included in LoseIt membership — not billed separately
  • Named clinical team: founded by Jenni Haan, MPAS, PA-C (18+ years experience) with four additional credentialed providers
  • Slimpossible app + secure messaging for ongoing support between provider visits
  • HSA/FSA accepted; Cherry third-party financing available for patients needing payment plans

Where it loses points

  • Membership fee ($75/month) stacks on top of separately billed medication — total spend $205–$524/month depending on dose
  • No LegitScript certification or independent third-party accreditation disclosed
  • States served not publicly listed; availability depends on individual provider licensure
  • All medication sales are final once shipped; consultation fee non-refundable once completed
  • Compounding pharmacy partner not named on any public page
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard